Tonix Pharmaceuticals appoints Carolyn E. Taylor to Board of Directors

Tonix Pharmaceuticals Holding Corp.

Carolyn E. Taylor appointed to Board effective July 16, 2021, increasing board size to eight.
Taylor brings 35+ years of corporate law experience, including partner at Covington & Burling.
Granted 237,437 stock options vesting at 2022 annual meeting, exercisable at $0.98 per share.
Will receive annual retainer of $50,000 for board service.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Carolyn E. Taylor

director

TNXP · Tonix Pharmaceuticals Holding Corp.

Effective: 2021-07-16
Filed: July 19, 2021, 7:59 PM ET

On July 16, 2021, the Directors (the “Board”) of Tonix Pharmaceuticals Holding Corp. (the “Company”), increased the size of the Board from seven to eight directors and, upon on the recommendation of its Nominating and Corporate Governance Committee, appointed Carolyn E. Taylor as director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carolyn E. Taylor was appointed as director at Tonix Pharmaceuticals Holding Corp..

Action: appointed
Role: director

Exact text from the filing

On July 16, 2021, the Directors (the “Board”) of Tonix Pharmaceuticals Holding Corp. (the “Company”), increased the size of the Board from seven to eight directors and, upon on the recommendation of its Nominating and Corporate Governance Committee, appointed Carolyn E. Taylor as director of the Company, effective immediately.

View on SEC.gov

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001387131-21-007425

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.